Stock RVMD REVOLUTION MEDICINES, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company Revolution Medicines, Inc.

Equities

RVMD

US76155X1000

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 21:30:01 03/05/2024 BST 		5-day change 1st Jan Change
40.2 USD +2.58% Intraday chart for Revolution Medicines, Inc. +11.79% +40.17%
04-12 Oppenheimer Adjusts Revolution Medicines Price Target to $45 From $43, Maintains Outperform Rating MT
04-12 Needham Adjusts Revolution Medicines' Price Target to $46 From $36, Keeps Buy Rating MT

Business Summary

Revolution Medicines, Inc. is a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers. The Company’s research and development pipeline comprises RAS(ON) inhibitors that bind directly to RAS variants, which it refers to as RAS(ON) Inhibitors, and RAS companion inhibitors that target key nodes in the RAS pathway or associated pathways, which it refers to as RAS Companion Inhibitors. Its RAS(ON) Inhibitors are designed to be used as monotherapy, in combination with other RAS(ON) Inhibitors and/or in combination with RAS Companion Inhibitors or other therapeutic agents. Its RAS Companion Inhibitors are designed primarily for combination treatment strategies centered on its RAS(ON) Inhibitors. The Company’s RAS(ON) Inhibitors RMC-6236 RMC-6291 and RMC-9805 are in clinical development. RMC-6236, its RASMULTI(ON) inhibitor, is designed as a potent, oral, RAS-selective tri-complex inhibitor of multiple RAS(ON) variants, including cancer drivers.

Number of employees: 378

Sales per Business

USD in Million2022Weight2023Weight Delta
Novel Targeted Therapies
100.0 %
35 100.0 % 12 100.0 % -67.27%

Sales per region

USD in Million2022Weight2023Weight Delta
United States
100.0 %
35 100.0 % 12 100.0 % -67.27%

Managers

Managers TitleAgeSince
Mark Goldsmith CEO
 Chief Executive Officer 62 30/09/14
Jack Anders DFI
 Director of Finance/CFO 47 31/07/18
Wally Reiher CTO
 Chief Tech/Sci/R&D Officer - 31/07/15
Wei Lin CTO
 Chief Tech/Sci/R&D Officer 63 31/03/23
Steve Kelsey CTO
 Chief Tech/Sci/R&D Officer 63 28/02/17
Peg Horn COO
 Chief Operating Officer 61 -
Linnet Zia PRN
 Corporate Officer/Principal - 28/02/19
Jeff Cislini LAW
 General Counsel 49 31/12/19
Daniel Simon PRN
 Corporate Officer/Principal - 31/08/22
Luan M. Wilfong HRO
 Human Resources Officer - -

Members of the board

Members of the board TitleAgeSince
Mark Goldsmith CEO
 Chief Executive Officer 62 30/09/14
Alexis Borisy BRD
 Director/Board Member 52 31/10/14
Sandra Horning BRD
 Director/Board Member 75 11-08
Barbara Weber BRD
 Director/Board Member 67 31/03/18
Thilo Schroeder BRD
 Director/Board Member 42 28/02/18
Lorence Kim BRD
 Director/Board Member 49 11/07/22
Elizabeth Anderson BRD
 Director/Board Member 66 28/02/15
Flavia Borellini BRD
 Director/Board Member 65 21/06/21
Sushil Patel BRD
 Director/Board Member 53 15/06/22

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 176,053,148 165,629,552 ( 94.08 %) 5,560,000 ( 3.158 %) 94.08 %

Shareholders

NameEquities%Valuation
Wellington Management Co. LLP
9.036 %
14,882,086 9.036 % 480 M $
Vanguard Fiduciary Trust Co.
8.886 %
14,634,391 8.886 % 472 M $
BlackRock Advisors LLC
7.239 %
11,922,156 7.239 % 384 M $
Farallon Capital Management LLC
4.091 %
6,736,854 4.091 % 217 M $
Nextech Invest AG
3.823 %
6,296,740 3.823 % 203 M $
STATE STREET CORPORATION
3.797 %
6,253,361 3.797 % 202 M $
BVF, Inc.
3.632 %
5,981,212 3.632 % 193 M $
Casdin Capital LLC
3.470 %
5,714,775 3.470 % 184 M $
ALPHABET INC.
3.219 %
5,301,512 3.219 % 171 M $
Baker Bros. Advisors LP
3.126 %
5,148,657 3.126 % 166 M $
NameEquities%Valuation
T Rowe Price Associates, Inc. (13F Subfiler)
-
5,244,827 - 959 803 $
D.E. Shaw & Co., Inc.
-
1,347,439 - 246 581 $
Walleye Capital LLC
-
595,986 - 109 065 $
Adage Capital Partners GP LLC
-
500,000 - 91 500 $
Soros Capital Management LLC
-
364,824 - 66 763 $
TD Asset Management, Inc. (13F Subfiler)
-
312,396 - 57 168 $
Perceptive Advisors LLC
-
250,000 - 45 750 $
Bleichroeder LP
-
200,000 - 36 600 $
Sculptor Capital LP
-
178,107 - 32 594 $
Davidson Kempner Capital Management LP
-
150,000 - 27 450 $

Company contact information

Revolution Medicines, Inc.

700 Saginaw Drive

94063, Redwood City

+650 481 6801

http://www.revmed.com
address Revolution Medicines, Inc.(RVMD)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Other Biotechnology & Medical Research

Ratings for Revolution Medicines, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
13
Last Close Price
40.2 USD
Average target price
41.58 USD
Spread / Average Target
+3.44%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
REVOLUTION MEDICINES, INC. Stock Revolution Medicines, Inc.
+40.17% 6.85B
MODERNA, INC. Stock Moderna, Inc.
+25.69% 47.86B
LONZA GROUP AG Stock Lonza Group AG
+46.90% 41.42B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-3.46% 40.66B
CELLTRION, INC. Stock Celltrion, Inc.
-6.20% 28.92B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+9.17% 25.55B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-20.42% 19.27B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
+0.17% 12.15B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+28.07% 12.14B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-1.24% 11.99B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. RVMD Stock
  4. Company Revolution Medicines, Inc.